Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Rating of “Buy” from Analysts

Janux Therapeutics, Inc. (NASDAQ:JANX) has earned an average recommendation of “Buy” from the seven analysts that are currently covering the company, MarketBeat.com reports. Seven investment analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $61.33.

A number of brokerages recently commented on JANX. Wedbush reaffirmed an “outperform” rating and issued a $53.00 price target on shares of Janux Therapeutics in a research note on Monday, March 11th. BTIG Research assumed coverage on shares of Janux Therapeutics in a report on Thursday, March 21st. They issued a “buy” rating and a $62.00 price objective for the company. William Blair reaffirmed an “outperform” rating on shares of Janux Therapeutics in a research report on Tuesday, February 27th. Cantor Fitzgerald started coverage on Janux Therapeutics in a report on Wednesday, March 20th. They issued an “overweight” rating and a $100.00 price objective for the company. Finally, Jonestrading began coverage on shares of Janux Therapeutics in a report on Tuesday. They set a “buy” rating and a $70.00 target price on the stock.

Janux Therapeutics Stock Down 0.3 %

JANX opened at $48.69 on Monday. The company’s 50-day moving average price is $35.20 and its two-hundred day moving average price is $18.09. Janux Therapeutics has a twelve month low of $5.65 and a twelve month high of $58.69. The stock has a market cap of $2.52 billion, a price-to-earnings ratio of -36.34 and a beta of 4.18.

Janux Therapeutics (NASDAQ:JANX) last posted its earnings results on Friday, March 8th. The company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.12. The business had revenue of $2.46 million during the quarter, compared to analyst estimates of $0.98 million. Janux Therapeutics had a negative return on equity of 17.88% and a negative net margin of 721.18%. As a group, sell-side analysts anticipate that Janux Therapeutics will post -1.41 earnings per share for the current year.

Institutional Trading of Janux Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Nisa Investment Advisors LLC lifted its stake in shares of Janux Therapeutics by 10,740.0% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,710 shares of the company’s stock valued at $29,000 after purchasing an additional 2,685 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Janux Therapeutics by 149.4% during the 1st quarter. Tower Research Capital LLC TRC now owns 3,344 shares of the company’s stock worth $40,000 after purchasing an additional 2,003 shares during the period. China Universal Asset Management Co. Ltd. bought a new position in Janux Therapeutics during the 4th quarter valued at about $57,000. Barclays PLC lifted its stake in Janux Therapeutics by 533.0% in the fourth quarter. Barclays PLC now owns 4,608 shares of the company’s stock worth $61,000 after purchasing an additional 3,880 shares during the last quarter. Finally, Citigroup Inc. boosted its position in shares of Janux Therapeutics by 935.2% during the second quarter. Citigroup Inc. now owns 5,787 shares of the company’s stock valued at $69,000 after buying an additional 5,228 shares during the period. Hedge funds and other institutional investors own 75.39% of the company’s stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.